FDA 510(k) is a premarket notification submitted to the U.S. Food and Drug Administration to show that a medical device is substantially equivalent to a legally marketed predicate device. A successful 510(k) results in FDA clearance, not approval, allowing the device to be legally marketed in the United States.
What is FDA 510(k)?
FDA 510(k) takes its name from Section 510(k) of the Federal Food, Drug, and Cosmetic Act. Most Class II medical devices, along with certain Class I and Class III devices, enter the U.S. market through this pathway instead of Premarket Approval (PMA).
The principle behind the process is substantial equivalence. Rather than proving safety and effectiveness from the beginning, the manufacturer demonstrates that its device has the same intended use and either the same technological characteristics or different technological characteristics that do not raise new questions of safety and effectiveness, compared with a legally marketed predicate device.
If the FDA agrees, it issues a Substantially Equivalent (SE) determination, commonly referred to as 510(k) clearance. Clearance authorizes commercial distribution in the United States but is legally different from FDA approval.
Why FDA 510(k) matters in medical device development
A required 510(k) is the legal gateway to the U.S. market. Marketing a device that requires clearance without obtaining it can cause the FDA to consider the device adulterated or misbranded, potentially resulting in warning letters, import detention, recalls, seizures, civil penalties, or injunctions.
The pathway also drives the development strategy. Predicate selection influences device design, testing requirements, labeling, timelines, and regulatory costs. Although the FDA’s review goal for a Traditional 510(k) is 90 FDA review days, real-world timelines frequently extend because of Additional Information (AI) requests, incomplete testing, or poor predicate selection.
The original clearance also establishes the regulatory baseline for future product modifications. Manufacturers must continually assess whether design or labeling changes require submission of a new 510(k).
How the FDA 510(k) process works
A 510(k) submission is a structured technical comparison governed by 21 CFR Part 807 Subpart E. Since October 1, 2023, nearly all submissions must be prepared electronically using the FDA’s eSTAR template.
A typical workflow includes:
- Identify a predicate device. Select one or more legally marketed devices with the same intended use and comparable technological characteristics.
- Confirm regulatory classification. Verify the product code, regulation number, device class, and whether a 510(k), De Novo, PMA, or exemption applies.
- Generate supporting evidence. Depending on the device, this may include:
- Bench performance testing
- Biocompatibility (ISO 10993)
- Sterile barrier validation (ISO 11607)
- Electrical safety and EMC (IEC 60601-1)
- Software lifecycle documentation (IEC 62304)
- Cybersecurity documentation
- Risk management (ISO 14971)
- Prepare the eSTAR submission. Include device description, indications for use, substantial equivalence comparison, labeling, sterilization information, software documentation, performance testing, and declarations.
- Acceptance Review. FDA performs a Refuse-to-Accept (RTA) screening within 15 calendar days to verify administrative completeness.
- Substantive Review. FDA evaluates the scientific evidence and may issue one or more Additional Information (AI) requests.
- Clearance. Once substantial equivalence is established, the FDA issues an SE letter, and the device may be commercially marketed.
The submission is supported by documentation generated through the manufacturer’s Quality Management System. Since February 2, 2026, these quality system requirements are governed by the FDA’s Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 by reference.
Common challenges and best practices
The most common cause of delay is selecting the wrong predicate. A predicate with a different intended use or significantly different technology can result in a Not Substantially Equivalent (NSE) decision or force additional testing.
Incomplete testing is another frequent issue. FDA reviewers commonly identify missing performance data, insufficient validation, inconsistent labeling, or incomplete software documentation during review.
Successful programs typically:
- Select and justify the predicate before design freeze.
- Use the FDA’s Q-Submission (Pre-Sub) program to obtain feedback on testing plans.
- Build substantial equivalence tables that clearly compare intended use, technological characteristics, performance testing, and labeling.
- Align design controls, risk management, verification, validation, and labeling from the beginning rather than reconstructing documentation before submission.
- Ensure every performance claim is supported by objective evidence.
These practices significantly reduce review cycles and improve the likelihood of first-pass clearance.
How SJML helps with FDA 510(k)
SJML supports FDA 510(k) submissions through its Compliance-as-a-Service offering. Its regulatory specialists assist with device classification, regulatory pathway selection, predicate strategy, and preparation of the complete submission package.
Because SJML integrates product development, engineering, manufacturing, testing, and QARA under one organization, the evidence required for a successful 510(k)—including ISO 14971 risk management, IEC 62304 software documentation, IEC 60601 safety testing, verification and validation reports, and Design History File (DHF) documentation—is developed alongside the product rather than assembled after development is complete.
Frequently asked questions
No. A 510(k) results in FDA clearance, while a Premarket Approval (PMA) results in FDA approval.
A cleared device has been found substantially equivalent to a legally marketed predicate. An approved device has independently demonstrated safety and effectiveness through the PMA process, typically with extensive clinical evidence. Using the phrase “FDA approved” for a 510(k)-cleared device is considered misleading and may create regulatory issues.
The FDA’s review goal for a Traditional 510(k) is 90 FDA review days after acceptance.
In practice, total project timelines are much longer. Predicate research, laboratory testing, documentation preparation, and responses to FDA Additional Information requests commonly extend the overall timeline to six months to one year, depending on device complexity.
There are three primary submission types:
Traditional 510(k): The standard pathway used for most new devices and major modifications.
Special 510(k): Used for certain modifications to a manufacturer’s own legally marketed device when design controls adequately support the change.
Abbreviated 510(k): Uses FDA-recognized consensus standards, guidance documents, and special controls to streamline portions of the submission where appropriate.
Each pathway ultimately requires the manufacturer to demonstrate substantial equivalence.
A predicate device is a legally marketed medical device used as the comparison device for establishing substantial equivalence.
A valid predicate may be:
A device marketed before May 28, 1976 (pre-amendments device)
A device reclassified from Class III
A device previously cleared through the 510(k) process.
Choosing an inappropriate predicate is one of the most common reasons for FDA review delays, Additional Information requests, or a Not Substantially Equivalent determination.
Related terms
- Premarket Approval (PMA)
- Substantial Equivalence
- Predicate Device
- De Novo Classification
- Quality Management System Regulation (QMSR)
